|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MANEAL |
Gene summary for MANEAL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MANEAL | Gene ID | 149175 |
| Gene name | mannosidase endo-alpha like | |
| Gene Alias | MANEAL | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0000139 | UniProtAcc | Q5VSG8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 149175 | MANEAL | HCC1 | Human | Liver | HCC | 6.31e-22 | 2.90e+00 | 0.5336 |
| 149175 | MANEAL | HCC2 | Human | Liver | HCC | 2.06e-27 | 2.50e+00 | 0.5341 |
| 149175 | MANEAL | HCC5 | Human | Liver | HCC | 8.51e-11 | 8.94e-01 | 0.4932 |
| 149175 | MANEAL | S014 | Human | Liver | HCC | 4.58e-05 | 2.02e-01 | 0.2254 |
| 149175 | MANEAL | S015 | Human | Liver | HCC | 9.93e-07 | 2.54e-01 | 0.2375 |
| 149175 | MANEAL | S016 | Human | Liver | HCC | 4.05e-10 | 2.88e-01 | 0.2243 |
| 149175 | MANEAL | S027 | Human | Liver | HCC | 2.94e-16 | 6.68e-01 | 0.2446 |
| 149175 | MANEAL | S028 | Human | Liver | HCC | 8.22e-26 | 7.22e-01 | 0.2503 |
| 149175 | MANEAL | S029 | Human | Liver | HCC | 3.74e-26 | 7.28e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664N>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664N>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-AN-A0XR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664N>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664N>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664N>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-AQ-A1H3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664N>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664G>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664N>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-BH-A0DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664G>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MANEAL | SNV | Missense_Mutation | rs766850516 | c.664N>C | p.Ala222Pro | p.A222P | Q5VSG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-BH-A1FH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |